EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083

Brett Hanscom iD, Mark A Marzinke, Xinnong Li iD, Deborah Donnell iD, Robert Bies iD, Craig W Hendrix iD, Zhe Wang, Carolina Acuipil iD, Alex Rinehart, Jon W Collins, James F Rooney, Lydia Soto Torres und 9 weitere

The Journal of Infectious Diseases · 2026

DOI: 10.1093/infdis/jiaf561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Brett Hanscom und 20 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: HIV Infections, Transgender Persons, Pre-Exposure Prophylaxis, Homosexuality, Male. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDA NIH HHS, NIMH NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The HIV Prevention Trials Network (HPTN) 083 Trial demonstrated the superiority of long-acting, injectable cabotegravir (CAB) over daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis among cisgender men (MSM) and transgender women (TGW) who have sex with men. Plasma CAB concentrations associated with HIV protection in humans are unknown.

Methods

We conducted a nested case-control study to investigate the association between plasma CAB concentrations and HIV risk. Plasma CAB concentrations were estimated for participants with confirmed HIV and for HIV-negative controls, who were matched on region, gender, and race. The window of HIV acquisition for cases was defined as the time between the last HIV-negative visit and the first HIV-positive visit; this window was used to evaluate CAB exposure for cases and their matched controls. Participants were categorized by the minimum estimated CAB concentration (CABmin) during this window relative to the protein-adjusted 90% CAB inhibitory concentration (1× PA-IC90) and 4× PA-IC90. HIV risk was modeled using conditional logistic regression.

Results

Plasma CABmin was ≥4× PA-IC90 in 26% of HIV-positive cases, compared with 76% of matched controls. Plasma CABmin ≥4× PA-IC90 was associated with a 93% reduction in risk of HIV acquisition compared with CABmin <1× PA-IC90 (95% CI: 76%, 98%, P < .001). CABmin between 1× and 4× PA-IC90 had an estimated risk reduction of 79% compared with CABmin <1× PA-IC90 (95% CI: −19%, 96%, P = .07).

Conclusions

Consistent plasma CAB concentrations ≥4× PA-IC90 were estimated to provide 93% protection against HIV in MSM and TGW.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsTransgender PersonsPre-Exposure ProphylaxisHomosexuality, MaleAnti-HIV AgentsPyridonesHumansMaleAdultCase-Control StudiesFemaleYoung AdultMiddle AgedTenofovirDiketopiperazines

Stichwörter der Autor:innen

HIV PrEPHPTN 083cabotegravircabotegravir pharmacokineticslong-acting PrEP

Substanzen

Anti-HIV AgentscabotegravirPyridonesTenofovirDiketopiperazines

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
  • John Hopkins School of Medicine, John Hopkins University, Baltimore, Maryland, USA.
  • School of Pharmacy and Pharmaceutical Sciences, University of Buffalo, Buffalo, New York, USA.
  • ViiV Healthcare, Durham, North Carolina, USA.
  • Gilead Sciences, Foster City, California, USA.
  • NIH Division of AIDS, Bethesda, Maryland, USA.

ORCID-Profile: Brett Hanscom, Xinnong Li, Deborah Donnell, Robert Bies, Craig W Hendrix, Carolina Acuipil, Paul Richardson, Suwat Chariyalerstsak, Christopher B Hurt, Manya Magnus, Raphael J Landovitz

Förderung

  • NIDA NIH HHS
  • NIMH NIH HHS
  • NIAID NIH HHS
  • Gilead Sciences
  • ViiV Healthcare
  • NIH HHS
  • HIV Prevention Trials Network [HPTN] Leadership and Operations Center
  • HPTN Statistical and Data Management Center

Zitieren

APA

Hanscom, B., Marzinke, M. A., Li, X., Donnell, D., Bies, R., Hendrix, C. W., Wang, Z., Acuipil, C., Rinehart, A., Collins, J. W., Rooney, J. F., Soto Torres, L., Richardson, P., Chariyalerstsak, S., Valdez Ramalho Madruga, J., Hurt, C. B., Magnus, M., Frank, I., McCauley, M., …, & Landovitz, R. J. (2026). Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf561

Vancouver

Hanscom B, Marzinke MA, Li X, Donnell D, Bies R, Hendrix CW, et al. Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf561

BibTeX
@article{Hanscom2026,
  author = {Hanscom, Brett and Marzinke, Mark A and Li, Xinnong and Donnell, Deborah and Bies, Robert and Hendrix, Craig W and Wang, Zhe and Acuipil, Carolina and Rinehart, Alex and Collins, Jon W and Rooney, James F and Soto Torres, Lydia and Richardson, Paul and Chariyalerstsak, Suwat and Valdez Ramalho Madruga, Jose and Hurt, Christopher B and Magnus, Manya and Frank, Ian and McCauley, Marybeth and Grinsztejn, Beatriz and Landovitz, Raphael J},
  title = {Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  doi = {10.1093/infdis/jiaf561}
}
Kostenlos starten →